Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:country |
gptkb:Germany
|
| gptkbp:focus |
Biopharmaceuticals
Animal health Human pharmaceuticals |
| gptkbp:foundedYear |
1885
|
| gptkbp:founder |
gptkb:Albert_Boehringer
|
| gptkbp:hasResearchCenter |
gptkb:Vienna,_Austria
gptkb:Biberach,_Germany gptkb:Ridgefield,_Connecticut,_USA |
| gptkbp:headquartersLocation |
Ingelheim am Rhein, Germany
|
| https://www.w3.org/2000/01/rdf-schema#label |
Boehringer Ingelheim
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:keyPerson |
gptkb:Hubertus_von_Baumbach
gptkb:Jean_Scheftsik_de_Szolnok gptkb:Michael_Schmelmer |
| gptkbp:logo |
Boehringer Ingelheim logo.svg
|
| gptkbp:market |
Global
|
| gptkbp:memberOf |
gptkb:International_Federation_of_Pharmaceutical_Manufacturers_&_Associations
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations |
| gptkbp:notableAcquisition |
Merial (animal health business from Sanofi, 2017)
|
| gptkbp:notableEvent |
Acquisition of Abexxa Biologics (2021)
Acquisition of Actimis Pharmaceuticals (2008) Acquisition of Fort Dodge Animal Health (2010) Acquisition of GENEART (2010) Acquisition of ICD Therapeutics (2019) Acquisition of Labor Dr. Merk & Kollegen (2019) Acquisition of NBE-Therapeutics (2020) Acquisition of Northern Biologics (2020) Acquisition of Pharmaxis (2015) Acquisition of T3 Pharmaceuticals (2022) Acquisition of Trutino Biosciences (2022) Acquisition of ViraTherapeutics (2018) Acquisition of Zelnorm rights (2015) COVID-19 research and development Development of SGLT2 inhibitor (Jardiance) Development of Spiriva for COPD Development of anticoagulant Pradaxa Development of biosimilar Cyltezo Acquisition of Amgen's biopharmaceutical manufacturing facility in Fremont, California (2011) Development of Ofev for idiopathic pulmonary fibrosis |
| gptkbp:numberOfEmployees |
~52,000
|
| gptkbp:parentCompany |
gptkb:Boehringer_Ingelheim_Group
|
| gptkbp:product |
gptkb:Cyltezo
gptkb:Metacam gptkb:Mobic gptkb:Ofev gptkb:Pradaxa gptkb:Spiriva gptkb:Jardiance |
| gptkbp:revenue |
~€24 billion (2022)
|
| gptkbp:stockExchange |
Not publicly listed
|
| gptkbp:subsidiary |
gptkb:Boehringer_Ingelheim_Animal_Health
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
https://www.boehringer-ingelheim.com/
|
| gptkbp:bfsParent |
gptkb:礼来公司
gptkb:NOVN |
| gptkbp:bfsLayer |
5
|